Literature DB >> 3484365

Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption.

N F Ho1.   

Abstract

On the basis of the enterohepatocycling phenomenon of bile acids involving the intestines, liver, and gallbladder, it was conceptualized that bile acids could serve as a molecular carrier of drugs by taking advantage of the bile acid active transport mechanism. It was further proposed that derivatization or analogation of bile acids at the C3-OH position was the desired route because of the reactive hydroxyl group and, moreover, because of the active transport requirement of retaining the C17 side chain with a single terminal acidic function. Using 3-tosylcholic, 3-benzoylcholic, and 3-iodocholic acids, in situ liver absorption, biliary excretion, and intestinal absorption studies in the rat were successful in establishing the concept that C3-derivatives and analogs of bile acids are, potentially, novel molecular delivery systems for intestinal and liver-site directed absorption.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3484365     DOI: 10.1111/j.1749-6632.1987.tb45811.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Novel (64)Cu-radiolabeled bile acid conjugates for targeted PET imaging.

Authors:  Hyun-Soon Chong; Yunwei Chen; Chi Soo Kang; Xiang Sun; Ningjie Wu
Journal:  Bioorg Med Chem Lett       Date:  2015-01-12       Impact factor: 2.823

2.  Intestinal transport of gentamicin with a novel, glycosteroid drug transport agent.

Authors:  H R Axelrod; J S Kim; C B Longley; E Lipka; G L Amidon; R Kakarla; Y W Hui; S J Weber; S Choe; M J Sofia
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

Review 3.  Biology of membrane transport proteins.

Authors:  W Sadée; V Drübbisch; G L Amidon
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

4.  Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.

Authors:  M Kågedahl; P W Swaan; C T Redemann; M Tang; C S Craik; F C Szoka; S Oie
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

5.  Transepithelial transport of tyramine across filter-grown MDCK cells via a poly(D-lysine) carrier.

Authors:  M E Taub; J Wan; W C Shen
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

6.  Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids.

Authors:  Zhe Zhang; Hongxiang Li; Guangrui Xu; Ping Yao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 7.  Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows.

Authors:  Giovanni Addolorato; Gabriele A Vassallo; Antonio Mirijello; Antonio Gasbarrini
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

Review 8.  Plasma membrane transporters in modern liver pharmacology.

Authors:  Jose J G Marin
Journal:  Scientifica (Cairo)       Date:  2012-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.